downgrad neutral organ acceler
elsewher life scienc lonn
downgrad buy neutral expect growth
earn in-lin expect growth next year
limit upsid potenti focus slower growth pharmaceut
qc face competit biolog research sale forc reorgan
take time gain traction see revenu visibl high china growth
earn visibl billion three year share repurchas author
lower fair valu reflect mid-point peer valuat
see acceler elsewher life scienc tool initi coverag
lonza lonn-buy recent view world lead posit biolog
product posit compani acceler growth expect
modest acceler thermo fisher tmo-buy billion
bioproduct exposur agil a-buy strong product cycl move
growth higher
see sale rang view reorgan mass spec
sale forc focu pharmaceut qc strong competit thermo
fisher sciex agil biolog limit growth upsid rel
organ growth guidanc year estim
growth well
visibl asia biolog share repurchas sale
asia custom base retool biolog qc billion share
repurchas program see good visibl guid revenu earn
fair valu lower fair valu fv base
ev/ebitda multipl midpoint peer group
fv variou peer base ev/ebitda multipl includ
previou fv
base ev/ebitda multipl
million except per share data
growth asia estim
total sale geographi
total sale end-market
geograp sale
total sale
amort intang other
annual revenu break-out margin
total sale
amort intangilb
revenu
